blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4171497

EP4171497 - AZOXYSTROBIN EFFICACY IN PERSONAL CARE FORMULATIONS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  31.03.2023
Database last updated on 03.09.2024
FormerThe international publication has been made
Status updated on  31.12.2021
Formerunknown
Status updated on  29.01.2021
Most recent event   Tooltip15.11.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
The Procter & Gamble Company
One Procter & Gamble Plaza
Cincinnati, OH 45202 / US
[2023/18]
Inventor(s)01 / JOHNSON, Eric, Scott
Cincinnati, Ohio 45202 / US
02 / RICHARDS, Jeanette, Anthea
Cincinnati, Ohio 45202 / US
03 / WISE, Geoffrey, Marc
Cincinnati, Ohio 45202 / US
04 / CHANG, Debora, W.
Cincinnati, Ohio 45202 / US
05 / HENRY, James, Patrick
Cincinnati, Ohio 45202 / US
06 / CATERINO, Tamara, Lynn
Cincinnati, Ohio 45202 / US
 [2023/18]
Representative(s)P&G Patent Germany
Procter & Gamble Service GmbH
Sulzbacher Straße 40
65824 Schwalbach am Taunus / DE
[2023/18]
Application number, filing date20842774.018.12.2020
[2023/18]
WO2020US65813
Priority number, dateUS202063044814P26.06.2020         Original published format: US 202063044814 P
[2023/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021262229
Date:30.12.2021
Language:EN
[2021/52]
Type: A1 Application with search report 
No.:EP4171497
Date:03.05.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 30.12.2021 takes the place of the publication of the European patent application.
[2023/18]
Search report(s)International search report - published on:EP30.12.2021
ClassificationIPC:A61K8/49, A61Q5/00
[2023/18]
CPC:
A61K8/4953 (EP,US); A61K8/89 (US); A61Q19/10 (EP,US);
A61Q5/006 (EP); A61Q5/02 (EP,US); A61Q5/12 (EP,US);
A61Q19/00 (EP); A61Q9/02 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/18]
TitleGerman:AZOXYSTROBINWIRKUNG IN KÖRPERPFLEGEFORMULIERUNGEN[2023/18]
English:AZOXYSTROBIN EFFICACY IN PERSONAL CARE FORMULATIONS[2023/18]
French:EFFICACITÉ DE L'AZOXYSTROBINE DANS DES FORMULATIONS DE SOINS PERSONNELS[2023/18]
Entry into regional phase12.12.2022National basic fee paid 
12.12.2022Designation fee(s) paid 
12.12.2022Examination fee paid 
Examination procedure12.12.2022Examination requested  [2023/18]
12.12.2022Date on which the examining division has become responsible
14.08.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
12.12.2022Renewal fee patent year 03
15.11.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XY]US2016310393  (CHANG DEBORA W [US], et al) [X] 1-6,8,10-15 * paragraph [0029]; claims 1-7,12-24 * [Y] 1-15;
 [X]CN109700877  (SHENZHEN LLG BIOTECHNOLOGY CO LTD) [X] 1,2,4-6,8,11,12 * paragraph [0056]; claim - *;
 [X]CN109757493  (ANYANG QUANFENG BIOLOGICAL TECH CO LTD) [X] 1-8,10-13 * paragraph [0033]; examples 1-4 *;
 [X]CN110025658  (COSMETICS CO LTD GUANGZHOU CHINA MING YAN) [X] 1-6,8,12-15 * paragraphs [0002] - [0008] - [ 0033]; table 3 * * paragraphs [0060] , [0062] , [0077] , [0094] *;
 [X]CN110420131  (ZHENJIANG DAMEIRUIZHEN MADISON BIO TECH CO LTD) [X] 1-6,8,13-15 * paragraphs [0024] , [0029] , [0057]; examples 1-4 *;
 [E]WO2020264577  (PROCTER & GAMBLE [US]) [E] 1-6,8,10-15 * page 1, line 16; example -; claim - *;
 [E]WO2021051133  (PROCTER & GAMBLE [US]) [E] 1,2,4-8,10,11,14,15 * page 41, lines 9-10 ** page 50, lines 24-25 *;
 [Y]  - Piérard-Franchimont C ET AL, "Effect of residence time on the efficacy of antidandruff shampoos", International Journal of Cosmetic Science, doi:10.1111/j.1467-2494.2003.00195.x, (20030630), URL: https://doi.org/10.1111/j.1467-2494.2003.00195.x, (20210413), XP055794760 [Y] 1-15 * "Introduction" p.267 *

DOI:   http://dx.doi.org/10.1111/j.1467-2494.2003.00195.x
by applicantUS2396278
 US2438091
 US2486921
 US2486922
 US2528378
 US2658072
 US3929678
 US4275055
 US5104646
 US5106609
 US2006257349
 US2009155383
 US2009221463
 US2009232873
 US2010179083
 US8440605
    - CAS , no. 131860-33-8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.